BigHat Biosciences, a San Mateo, CA-bases biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, announced that it raised a $75 million Series B funding. The round was led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille …
SupplyPike, a Fayetteville-based supply chain SaaS company, raised $25 million in Series B funding. The fund was led by Noro-Moseley Partners and Frontier Growth invested in the four-year-old company’s Series B and investors from there will be joining SupplyPike’s board, which also includes existing investors at Blumberg Capital. The company …
Delfi Diagnostics, Inc., a Baltimore and Palo Alto, CA-based developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, announced that it raised $225 million in Series B. This round of financing was led by DFJ Growth with participation from Eli Lilly and …
AppViewX, a New York-based leader in automated machine identity management (MIM) and application infrastructure security, announced that it raised $20 million in Series B funding. The round was led by a growth equity firm and existing investor, Brighton Park Capital (“Brighton Park”). The additional investment will help maximize AppViewX’s go-to-market …
Keen Decision Systems, a Durham, NC-based software-as-a-service company whose unified marketing measurement and optimization platform announced today that it has closed an $11 million Series B. The round was led by Ballast Point Ventures IV (“BPV”). The investment from Ballast Point Ventures will accelerate Keen’s product development and fuel Keen’s …
Canvas Medical, a San Francisco, CA-based EMR that enables clinicians and developers to power the future of care delivery, raised $24 million in Series B funding. The round was led by M13 with participation from Haystack and previous investors Inspired Capital, IA Ventures, Upfront Ventures, and Irongrey. With this funding, …
Delfi Diagnostics, a Palo Alto, CA-based pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, announced that it raised $225 million Series B funding. The round was led by DFJ Growth with participation from Eli Lilly and Company, Point72, Brown Advisory, …
